ZGNX Zogenix Inc.

14.55
+0.30  (2%)
Previous Close 14.25
Open 14.35
Price To book 4.55
Market Cap 361437714
Shares 24,841,080
Volume 1,173,939
Short Ratio 11.47
Av. Daily Volume 489,123

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial to be initiated 4Q 2017.
ZX008
Lennox-Gastaut syndrome
Approved July 16, 2009.
Sumavel
Migraine
Phase 3 enrollment due to be completed 3Q 2017.
ZX008 - Study 1504
Dravet syndrom
Phase 3 to be initiated by ZGNX once partner is found.
Relday
Schizophrenia
Approved October 25, 2013.
Zohydro ER
Moderate to severe pain
Phase 3 data due 3Q 2017.
ZX008 - (Study 1)
Dravet syndrom
Approved January 30, 2015.
Abuse deterrent formulations of Zohydro ER
Moderate to severe pain